French Competition Probe Targets Price Setting, Distribution, And Generic Rebates
Executive Summary
Four years after its last inquiry into competition in the pharmaceutical market, the French competition authority is to look into how the prices of medicines are set, the level of rebates in the generics market, and the “economic and competitive balance of the pharmaceutical distribution chain.”
You may also be interested in...
New Dutch ‘Excessive Price’ Watchdog Targets Leadiant’s Orphan Drug
A new Dutch foundation set up to address cases of what it says are excessive drug pricing says it plans to refer Leadiant Biosciences’ CDCA product for the rare genetic disease, cerebrotendinous xanthomatosis, to the competition authorities.
European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials
The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.
WHO To Review Impact Of Mechanism For Tackling Substandard & Falsified Drugs
Recent incidents of illness and death caused by contaminated cough syrups show that there is a need to review the “member state mechanism” that is intended to coordinate efforts to tackle poor quality medical products, the World Health Organization says.